Shire wins trial over ulcerative colitis drug

Shares in Shire have leapt after it announced Thursday evening that it had won a patent trial against Watson Laboratories over Lialda, one of its treatments for ulcerative colitis.

Shares in Shire have leapt after it announced Thursday evening that it had won a patent trial against Watson Laboratories over Lialda, one of its treatments for ulcerative colitis.

The group's subsidiary, Shire Developments, brought the litigation against the Florida-based firm which led to a five-day trial, the result of which was the judge confirming that Shire is entitled to an injunction, which he will issue separately.

The injunction prohibits the Food and Drug Association from approving the abbreviated new drug application (ANDA) formulation until the expiration of Shire's '720 patent in 2020.

In 2012 Lialda contributed $400m to Shire's sales, equal to 8.6% of its revenue, data from Bloomberg has shown.

"Shire is very pleased that the court has ruled in our favor. We rely on our patents to be able to continue to invest in therapies that bring value to our patients and their caregivers. This ruling supports the innovative therapies that we develop in order to improve the lives of ulcerative colitis patients," Roger Adsett, the head of Shire's GI Business Unit, said.

The share price leapt 5.33% to 2,037p by 09:00 Friday.

NR

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
Prepare for the end of the epic bubble in US stocks
US stockmarkets

Prepare for the end of the epic bubble in US stocks

US stocks are as expensive as they’ve ever been. How can you prepare your portfolio for a bubble bursting?
18 Jan 2021
The best investment trusts to buy for 2021
Investment trusts

The best investment trusts to buy for 2021

Sectors ranging from emerging markets to student accommodation look poised to do well this year, says David Stevenson, as he picks the best investment…
19 Jan 2021